May 1, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.31 EPS, expectations were $-1.06. Operator: Hello and welcome to the Phathom Pharmaceuticals’ First ...

The new agreement builds on the strategic license agreement concluded in November 2024, which granted ALK exclusive rights to commercialise neffy® globally, with exception of the USA, Australia, New ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability.

The Supreme Court has said doctors should prescribe only generic drugs. The court made the remark while hearing a PIL seeking ...

Discover X4 Pharmaceuticals' Q1 2025 updates, including mavorixafor's $1-2B U.S. market potential, trial progress, and WHIM syndrome commercialization.

In addition to cutting DTC spend, Phathom will also “suspend, defer, or slow” several of its ongoing clinical development ...

Doctors across the country should be mandated to prescribe only generic medicines instead of brand names, the Supreme Court ...

This year is shaping up to be a changing and challenging environment for sales. Economic uncertainty, digital transformation, supply chain disruptions, the Great Resignation, quiet-quitting, remote ...

It is Sonepar’s sixth U.S. operation with annual sales exceeding $1 billion. Springfield, Richards, Echo and Holt are now united under the Echo name, with Pepco is set to join in June. According to an ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Market access is about aligning internal strategies with external realities that often change without warning and at a ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...